Eli Lilly’s obesity and diabetes treatments fuel growth and spark bidding war

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled to $3.57 billion in the third quarter. Meanwhile, revenue ...

Eli Lilly partners with Walmart to sell weight loss drug directly to patients nationwide

Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication ...
STAT

Eli Lilly’s weight loss and diabetes drug tops Keytruda as world’s best-selling medicine

Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially ...

New Walmart Partnership to Let Patients Buy Eli Lilly's Zepbound Without Insurance Hassles

Eli Lilly partners with Walmart to sell its weight-loss drug Zepbound nationwide, giving patients easier, insurance-free access through LillyDirect.
Fierce Pharma

Lilly's Zepbound, Mounjaro show out with $10B quarter despite CVS formulary hitch

Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...

Eli Lilly: The Price Upside Just Increased

Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

Eli Lilly Boosts Its Outlook on High Demand for Popular Weight-Loss Drugs

Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro.  The company also recently announced a partnership with Walmart that will expand access to Zepbound ...

Lilly Beats on Q3 Earnings, Ups View, Mounjaro, Zepbound Drive Sales

Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year ...